Brief: Grand Pharmaceutical Group Says NMPA Approves GPN01020 For Phase II Clinical Trial
25/03/2026 10:25
March 25 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK: NMPA APPROVES GPN01020 FOR PHASE II CLINICAL TRIAL FOR MIGRAINE PREVENTION Further company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement